Evidence map›Paper›PMID 37397937›Full record

ReviewWorld journal of hepatology2023

Tumor budding as a potential prognostic marker in determining the behavior of primary liver cancers.

Betul Unal, Mennan Yigitcan Celik, Elif Ocak Gedik, Cumhur Ibrahim Bassorgun, Gulsum Ozlem Elpek

Abstract readReview
In one paragraph

Review in World journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Betul UnalDepartment of Pathology, Akdeniz University Medical School, Antalya 07070, Turkey.
Mennan Yigitcan CelikDepartment of Pathology, Akdeniz University Medical School, Antalya 07070, Turkey.
Elif Ocak GedikDepartment of Pathology, Akdeniz University Medical School, Antalya 07070, Turkey.
Cumhur Ibrahim BassorgunDepartment of Pathology, Akdeniz University Medical School, Antalya 07070, Turkey.
Gulsum Ozlem ElpekDepartment of Pathology, Akdeniz University Medical School, Antalya 07070, Turkey. elpek@akdeniz.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular (HCC) and intrahepatic cholangiocarcinoma (ICC), the most common primary tumors of the liver, are among the most important causes of cancer deaths worldwide. Because patients with primary liver tumors are frequently diagnosed at an advanced stage and have high mortality, many efforts have been made to identify new markers to determine their behavior and treatment, similar to those in other solid organ tumors. Recently, morphological assessment of tumor budding (TB) has been revealed as a promising prognostic finding to predict tumor behavior and survival across several different tumor types. Currently, the TB score in colorectal cancer has been revealed as an important parameter in pathology report protocols to determine the course of the disease. Regarding the liver, despite enormous data showing that many mechanisms involved in TB are associated with tumor behavior in both HCC and ICC, studies focusing on the role of TB in predicting the behavior and prognosis of these tumors have started to be investigated very recently. The purpose of this review is to present data about TB in primary tumors of the liver, pointing out the potential role of this parameter in determining the course of the disease, and emphasize the need to increase the number of further studies focusing on the evaluation of this parameter with an overview of the mechanisms involved in TB.

Indexed as

CholangiocarcinomaEpithelial-mesenchymal transitionHepatocellular carcinomaLiver cancerPrognosisTumor budding

Identifiers

PMID37397937
PMCPMC10308291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.